Dapagliflozin and Urinary Tract Infection Risk in Type 2 Diabetes: A Comprehensive Critical Review of Mechanistic, Randomized, and Real-World Evidence. Trop. j. pharm. life sci. 2026, 13 (5), 53-68. https://doi.org/10.61280/9h681f91.